These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 18854724)

  • 1. Assessing the efficacy of 2 years of maintenance treatment with venlafaxine extended release 75-225 mg/day in patients with recurrent major depression: a secondary analysis of data from the PREVENT study.
    Kornstein SG; Kocsis JH; Ahmed S; Thase M; Friedman ES; Dunlop BW; Yan B; Pedersen R; Ninan PT; Li T; Keller M
    Int Clin Psychopharmacol; 2008 Nov; 23(6):357-63. PubMed ID: 18854724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the 2-year and combined maintenance phases.
    Keller MB; Trivedi MH; Thase ME; Shelton RC; Kornstein SG; Nemeroff CB; Friedman ES; Gelenberg AJ; Kocsis JH; Dunner DL; Hirschfeld RM; Rothschild AJ; Ferguson JM; Schatzberg AF; Zajecka JM; Pedersen RD; Yan B; Ahmed S; Musgnung J; Ninan PT
    J Clin Psychiatry; 2007 Aug; 68(8):1246-56. PubMed ID: 17854250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing venlafaxine extended release and fluoxetine for preventing the recurrence of major depression: results from the PREVENT study.
    Thase ME; Gelenberg A; Kornstein SG; Kocsis JH; Trivedi MH; Ninan P; Li T; Pedersen R; Keller M
    J Psychiatr Res; 2011 Mar; 45(3):412-20. PubMed ID: 20801464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of sex and menopausal status on response, remission, and recurrence in patients with recurrent major depressive disorder treated with venlafaxine extended release or fluoxetine: analysis of data from the PREVENT study.
    Kornstein SG; Pedersen RD; Holland PJ; Nemeroff CB; Rothschild AJ; Thase ME; Trivedi MH; Ninan PT; Keller MB
    J Clin Psychiatry; 2014 Jan; 75(1):62-8. PubMed ID: 24345717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beyond remission: rationale and design of the Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study.
    Kornstein SG
    CNS Spectr; 2006 Dec; 11(12 Suppl 15):28-34. PubMed ID: 17146416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT Study.
    Kocsis JH; Thase ME; Trivedi MH; Shelton RC; Kornstein SG; Nemeroff CB; Friedman ES; Gelenberg AJ; Dunner DL; Hirschfeld RM; Rothschild AJ; Ferguson JM; Schatzberg AF; Zajecka JM; Pedersen RD; Yan B; Ahmed S; Musgnung J; Ninan PT; Keller MB
    J Clin Psychiatry; 2007 Jul; 68(7):1014-23. PubMed ID: 17685736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the acute and continuation phases.
    Keller MB; Trivedi MH; Thase ME; Shelton RC; Kornstein SG; Nemeroff CB; Friedman ES; Gelenberg AJ; Kocsis JH; Dunner DL; Dunlop BW; Hirschfeld RM; Rothschild AJ; Ferguson JM; Schatzberg AF; Zajecka JM; Pedersen R; Yan B; Ahmed S; Schmidt M; Ninan PT
    Biol Psychiatry; 2007 Dec; 62(12):1371-9. PubMed ID: 17825800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term function and psychosocial outcomes with venlafaxine extended release 75-225 mg/day versus placebo in the PREVENT study.
    Watanabe K; Thase ME; Kikuchi T; Tsuboi T; Asami Y; Pappadopulos E; Zhang M; Boucher M; Kornstein S
    Int Clin Psychopharmacol; 2017 Sep; 32(5):271-280. PubMed ID: 28598899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psychosocial outcomes in patients with recurrent major depressive disorder during 2 years of maintenance treatment with venlafaxine extended release.
    Trivedi MH; Dunner DL; Kornstein SG; Thase ME; Zajecka JM; Rothschild AJ; Friedman ES; Shelton RC; Keller MB; Kocsis JH; Gelenberg A
    J Affect Disord; 2010 Nov; 126(3):420-9. PubMed ID: 20510459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extended-release venlafaxine in relapse prevention for patients with major depressive disorder.
    Simon JS; Aguiar LM; Kunz NR; Lei D
    J Psychiatr Res; 2004; 38(3):249-57. PubMed ID: 15003430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maintenance therapy to prevent recurrence of depression: summary and implications of the PREVENT study.
    Kornstein SG
    Expert Rev Neurother; 2008 May; 8(5):737-42. PubMed ID: 18457530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing rates and predictors of tachyphylaxis during the prevention of recurrent episodes of depression with venlafaxine ER for two years (PREVENT) study.
    Rothschild AJ; Dunlop BW; Dunner DL; Friedman ES; Gelenberg A; Holland P; Kocsis JH; Kornstein SG; Shelton R; Trivedi MH; Zajecka JM; Goldstein C; Thase ME; Pedersen R; Keller MB
    Psychopharmacol Bull; 2009; 42(3):5-20. PubMed ID: 19752838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A meta-analysis of the efficacy of venlafaxine extended release 75-225 mg/day for the treatment of major depressive disorder.
    Thase M; Asami Y; Wajsbrot D; Dorries K; Boucher M; Pappadopulos E
    Curr Med Res Opin; 2017 Feb; 33(2):317-326. PubMed ID: 27794623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression.
    Rudolph RL; Feiger AD
    J Affect Disord; 1999 Dec; 56(2-3):171-81. PubMed ID: 10701474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial.
    Stein MB; Pollack MH; Bystritsky A; Kelsey JE; Mangano RM
    Psychopharmacology (Berl); 2005 Jan; 177(3):280-8. PubMed ID: 15258718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder.
    Pollack MH; Lepola U; Koponen H; Simon NM; Worthington JJ; Emilien G; Tzanis E; Salinas E; Whitaker T; Gao B
    Depress Anxiety; 2007; 24(1):1-14. PubMed ID: 16894619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.
    Hewett K; Chrzanowski W; Schmitz M; Savela A; Milanova V; Gee M; Krishen A; Millen L; Leary MO; Modell J
    J Psychopharmacol; 2009 Jul; 23(5):531-8. PubMed ID: 18635695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcomes following switch from venlafaxine ER to desvenlafaxine in nonresponders and responders.
    Guico-Pabia CJ; Jiang Q; Ninan PT; Thase ME
    Curr Med Res Opin; 2011 Sep; 27(9):1815-26. PubMed ID: 21812735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of venlafaxine extended release and a long-term extension study for patients with major depressive disorder in Japan.
    Higuchi T; Kamijima K; Nakagome K; Itamura R; Asami Y; Kuribayashi K; Imaeda T
    Int Clin Psychopharmacol; 2016 Jan; 31(1):8-19. PubMed ID: 26513202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms.
    Davidson JR; Meoni P; Haudiquet V; Cantillon M; Hackett D
    Depress Anxiety; 2002; 16(1):4-13. PubMed ID: 12203668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.